Thursday, October 25th, 2:00-3:25pm
Backed by the government’s strong commitment to promoting innovation in the biotech sector, new R&D structures in China have emerged in recent years. CRO’s have begun to move beyond their traditional service space and have launched their own drug development platforms, while domestic academic-industry collaborations continue to flourish. Chinese biotech companies are also looking closer to home for their next partner to foster an innovative drug development pipeline. This panel will discuss how the country’s focus on biotech innovation has spurred new models of R&D structures for Chinese companies.
- Jun Ren, MD, Founder & CEO, Newsummit Biopharma
- Edward Hu, Chief Operating Officer & Chief Financial Officer, WuXi AppTec
- Weishi Li, PhD, JD, Partner, Covington & Burling
- Yuelei Shen, PhD, President & CEO, Biocytogen
- Dan Zhang, MD, Chairman & CEO, Fountain Medical Development
Weishi Li, PhD, JD
Weishi Li is a partner in Covington's Beijing office and a member of the Life Sciences and Corporate Groups. Her practice covers a wide range of intellectual property and technology-related transactions across multiple technology sectors, including the life sciences, healthcare, and hi-tech industries. She has extensive experience assisting multinational companies and Chinese companies in structuring and negotiating cross-border IP and technology-related transactions such as licensing, strategic alliances, joint ventures, distribution and OEM relationship. Ms. Li also regularly provides IP counseling to leading PE/VC funds and multinational companies in investing into or acquiring technology and life sciences companies in China, including conducting substantive patent due diligence review on target companies.
Yuelei Shen, PhD
Dr. Yuelei Shen is the president and CEO of Biocytogen, a company devoting to providing the quickest mouse gene-targeting CRO service around the world, with the most competitive price. Biocytogen provides mouse gene-targeting CRO service to academic entities and pharmaceutical companies both in China and abroad (US, Europe).
Dr. Shen brings 20 years of expertise in immunology research and development to the Company. He has extensive experience in autoimmune disease research and generating knockout and knockin mice utilizing gene-targeting technology. Prior to Biocytogen, Dr. Shen worked on quality control of a polio vaccine, the MMR vaccine, and the Influenza virus vaccine at the National Institute for the Control of Pharmaceutical and Biological Products, State Food and Drug Administration, Beijing, China.
Dr. Shen received his PhD at University of Massachusetts Medical School with concentration studying MHC class I antigen presentation, mainly using molecular biology and biochemistry approaches. His post-doctorate work was performed at Howard Hughes Medical Institute/New York University School of Medicine. Dr. Shen’s work has focused on generating reporter mice. Prior to Biocytogen, he had designed and generated many gene-targeted mouse models and reporter mice. Using these mice, he studied EAE (multiple sclerosis mouse model), asthma, colitis, and arthritis.
Dan Zhang, MD
Dr. Dan Zhang has more than 15 years of drug development experience. He is the Chairman and CEO of Fountain Medical Development Ltd, a full-service clinical CRO with primary operation in South East Asia and China. FMD runs phase I/II/III operations in mainland China, Hong Kong, Taiwan and South Korea, central lab operation with the full support of regulatory affairs, data management and biostatistics, EDC and pharmacoeconomics operation.
Previously, Dr. Zhang was the Head of Clinical Development and Global Safety Assessment at Sigma-Tau Research Inc, a vice president at the Quintiles Transnational Corp., a member of Quintiles Executive Operation Committee, and also the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd. Before joining Quintiles, Dr. Zhang provided consulting services to many pharmaceutical, medical device and health insurance companies, such as Eli Lilly and Company, Pharmacia & Upjohn, Inc., Medtronic, Inc., and CIGNA Health Care.
Over the last 15 years, Dr. Zhang has established a strong working relationship with government and academic institutions in China. He is a member of the grant application review committee for the National Key Drug Development Fund jointly managed by the Ministry of Science & Technology (MOST) and Ministry of Public Health (MOPH). He chairs the Bayhelix’ SFDA working committee and works with the agency on the development of technical guidelines. Dr. Zhang is also a consultant for the State Food and Drug Administration (SFDA). He was a member of the Overseas Expert Committee on New Drug R&D from MOST. He was also a visiting professor at the Harbin Medical University of China. He is currently a senior consultant to Chinese Academy of Medical Sciences/Peking Union Medical College. Dr. Zhang was an Executive Director of Sino-American Professional Pharmaceutical Society (SAPA). He was the President (2006~2007) of the Chinese Biopharmaceutical Association-USA (CBA), and was a board of director of Bayhelix, a life-science organization for the senior executives from major pharmaceutical/biotech firms and for the founders of startup life sciences companies.
Dr. Zhang received his pre-med training from Peking University and received his MD from Peking Union Medical College. He continued his study at the Harvard School of Public Health and received an MPH in health policy and management. Then he continued his training at the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998 and is working on his PhD dissertation in the field of health economics and finance.